RU2448976C2 - Hcv/hiv inhibitors and their application - Google Patents
Hcv/hiv inhibitors and their application Download PDFInfo
- Publication number
- RU2448976C2 RU2448976C2 RU2008144299/04A RU2008144299A RU2448976C2 RU 2448976 C2 RU2448976 C2 RU 2448976C2 RU 2008144299/04 A RU2008144299/04 A RU 2008144299/04A RU 2008144299 A RU2008144299 A RU 2008144299A RU 2448976 C2 RU2448976 C2 RU 2448976C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- cycloalkyl
- substituted
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
FIELD: medicine, pharmaceutics.
SUBSTANCE: in claim described are organic compounds of formula I where radicals are given in description, which are applicable for elimination, prevention or alleviation of one or more symptoms, associated with HCV disorders.
EFFECT: obtaining pharmaceutical composition which possesses inhibiting activity with respect to NS3-4 HCV serinprotease, including formula I compound and pharmaceutically acceptable carrier.
30 cl, 25 ex, 2 tbl
Description
Claims (2)
или его фармацевтически приемлемая соль или его стереоизомер;
в которой у равен 1;
n равен 1;
R14 обозначает С(O);
R1 выбран из группы, включающей Н и С1-С4-алкил;
R2 выбран из группы, включающей С1-С4-алкил, С(O)С1-С4-алкил, С(O)ОС1-С4-алкил и С3-С6-циклоалкил-С0-С4-алкил;
или R1 и R2 вместе образуют циклопропановое кольцо, где циклопропановое кольцо может быть дополнительно замещено один или более раз;
W также выбран из группы, включающей С(O)-С(O)Н, C(=N-O-R24)-C(O)-аминогруппу, С(O)-С(O)-аминогруппу, C(O)NR24S(O)pR24, C(O)NR24S(O)pN(R24)2 и С(O)-[С(O)]а-гетероциклил, где гетероциклил может быть один или более раз независимо замещен арилом, C1-C4-алкилом, С1-С4-алкилом, замещенным одним или более атомами галогена, или С3-С6-циклоалкилом, где а равно 0 или 1, где каждый R24 независимо выбран из водорода или из группы, включающей С1-С4-алкил, С3-С6-циклоалкил-С0-С4-алкил, замещенный или незамещенный арил и замещенный или незамещенный гетероциклил, каждый из которых может быть один или более раз независимо замещен атомом галогена или C1-C4-алкилом;
V выбран из группы, включающей -Q1-Q2, где Q1 отсутствует, обозначает С(O), N(H), N(С1-С4-алкил), C=N(CN), C=N(SO2CH3), C=NCOH-C1-C4-алкил или C=N-COH, и Q2 обозначает водород или выбран из группы, включающей С1-С4-алкил, O-С1-С4-алкил, NH2, N(Н)-С1-С4-алкил, N(C1-C4-алкил)2, SО2-арил, SO2-С1-С4-алкил, С3-С6-циклоалкил-С0-С4-алкил, арил, гетероарил и гетероциклил, каждый из которых может быть один или более раз независимо замещен атомом галогена, С1-С4-алкилом, C1-C4-алкилом замещенным одним или более атомами галогена, или С3-С6-циклоалкилом;
р равен 0, 1 или 2;
R3 выбран из группы, включающей водород и С1-С4-алкил;
двухвалентный остаток:
выбран из группы, включающей:
, , ,
,
, , , ,
, ,
, , ,, ,
R8, R9 и R10 каждый независимо выбран из группы, включающей водород, С1-С4-алкил и С3-С6-циклоалкил-С0-С4-алкил;
R11 обозначает Н;
R12 обозначает С3-С6-циклоалкил; и
R13 обозначает Н;
где арил означает 5- и 6-членные моно- или полициклические ароматические группы;
гетероциклил означает 5-10-членный ароматический или неароматический гетероциклил, содержащий от 1 до 4 гетероатомов, выбранных из О, N и S;
и
гетероарил означает моноциклическое или бициклическое кольцо, содержащее до 7 атомов в каждом кольце, в котором по меньшей мере одно кольцо является ароматическим и содержит от 1 до 4 гетероатомов, выбранных из О, N и S.1. The compound of formula I:
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
in which y is 1;
n is 1;
R 14 is C (O);
R 1 is selected from the group consisting of H and C 1 -C 4 alkyl;
R 2 is selected from the group consisting of C 1 -C 4 -alkyl, C (O) C 1 -C 4 -alkyl, C (O) OC 1 -C 4 -alkyl and C 3 -C 6 -cycloalkyl-C 0 - C 4 -alkyl;
or R 1 and R 2 together form a cyclopropane ring, where the cyclopropane ring may be further substituted one or more times;
W is also selected from the group consisting of C (O) —C (O) H, C (= NOR 24 ) —C (O) amino group, C (O) —C (O) amino group, C (O) NR 24 S (O) p R 24 , C (O) NR 24 S (O) p N (R 24 ) 2 and C (O) - [C (O)] a- heterocyclyl, where heterocyclyl may be one or more times independently substituted by aryl, C 1 -C 4 alkyl, C 1 -C 4 alkyl substituted with one or more halogen atoms, or C 3 -C 6 cycloalkyl, where a is 0 or 1, where each R 24 is independently selected from hydrogen or from the group consisting of C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl-C 0 -C 4 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, each of which can is one or more times independently substituted by a halogen atom or C 1 -C 4 alkyl;
V is selected from the group consisting of -Q 1 -Q 2 , where Q 1 is absent, denotes C (O), N (H), N (C 1 -C 4 alkyl), C = N (CN), C = N (SO 2 CH 3 ), C = NCOH-C 1 -C 4 -alkyl or C = N-COH, and Q 2 is hydrogen or is selected from the group consisting of C 1 -C 4 -alkyl, O-C 1 -C 4- alkyl, NH 2 , N (H) -C 1 -C 4 -alkyl, N (C 1 -C 4 -alkyl) 2 , SO 2 -aryl, SO 2 -C 1 -C 4 -alkyl, C 3 -C 6 -cycloalkyl-C 0 -C 4 -alkyl, aryl, heteroaryl and heterocyclyl, each of which may be independently or independently substituted one or more times by a halogen atom, C 1 -C 4 -alkyl, C 1 -C 4 -alkyl substituted one or more halogen atoms, or C 3 -C 6 cycloalkyl;
p is 0, 1 or 2;
R 3 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl;
divalent residue:
selected from the group including:
, , ,
,
, , , ,
, ,
, , , , ,
R 8 , R 9 and R 10 are each independently selected from the group consisting of hydrogen, C 1 -C 4 alkyl and C 3 -C 6 cycloalkyl-C 0 -C 4 alkyl;
R 11 is H;
R 12 is C 3 -C 6 cycloalkyl; and
R 13 is H;
where aryl means 5- and 6-membered mono- or polycyclic aromatic groups;
heterocyclyl means a 5-10 membered aromatic or non-aromatic heterocyclyl containing from 1 to 4 heteroatoms selected from O, N and S;
and
heteroaryl means a monocyclic or bicyclic ring containing up to 7 atoms in each ring, in which at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from O, N and S.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79131806P | 2006-04-11 | 2006-04-11 | |
US60/791,318 | 2006-04-11 | ||
US86687406P | 2006-11-22 | 2006-11-22 | |
US60/866,874 | 2006-11-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008144299A RU2008144299A (en) | 2010-05-20 |
RU2448976C2 true RU2448976C2 (en) | 2012-04-27 |
Family
ID=38617501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008144299/04A RU2448976C2 (en) | 2006-04-11 | 2007-04-09 | Hcv/hiv inhibitors and their application |
Country Status (27)
Country | Link |
---|---|
US (4) | US7825152B2 (en) |
EP (2) | EP2007789B1 (en) |
JP (1) | JP5167244B2 (en) |
KR (1) | KR101059593B1 (en) |
CN (1) | CN101466727B (en) |
AR (1) | AR060405A1 (en) |
AU (1) | AU2007249668B2 (en) |
BR (1) | BRPI0710878A2 (en) |
CA (1) | CA2643680A1 (en) |
CL (1) | CL2007001005A1 (en) |
CR (1) | CR10336A (en) |
EC (1) | ECSP088811A (en) |
ES (1) | ES2543840T3 (en) |
HK (1) | HK1126798A1 (en) |
IL (1) | IL194434A0 (en) |
MA (1) | MA30392B1 (en) |
MX (1) | MX2008013119A (en) |
MY (1) | MY147247A (en) |
NO (1) | NO20084749L (en) |
NZ (1) | NZ571826A (en) |
PE (2) | PE20080072A1 (en) |
RU (1) | RU2448976C2 (en) |
SG (1) | SG173368A1 (en) |
TN (1) | TNSN08400A1 (en) |
TW (1) | TWI341207B (en) |
UA (1) | UA100666C2 (en) |
WO (1) | WO2007133865A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
BRPI0617274A2 (en) | 2005-10-11 | 2011-07-19 | Intermune Inc | compounds and methods for inhibiting hepatitis c viral replication |
CN101466727B (en) | 2006-04-11 | 2012-10-17 | 诺瓦提斯公司 | Hcv/hiv inhibitor and their uses |
RU2008152171A (en) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | NEW HEPATITIS C VIRAL REPLICATION INHIBITORS |
EP2185524A1 (en) * | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
KR101396696B1 (en) * | 2007-10-10 | 2014-05-16 | 노파르티스 아게 | Spiropyrrolidines and their use against hcv and hiv infection |
CA2722858C (en) | 2008-04-30 | 2017-08-29 | Siemens Medical Solutions Usa, Inc. | Substrate based pet imaging agents |
US20090285774A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8512690B2 (en) * | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
KR20140000689A (en) * | 2010-10-08 | 2014-01-03 | 노파르티스 아게 | Salts and polymorphs of sulfamide ns3 inhibitors |
AU2011311880B2 (en) | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
WO2013025858A1 (en) * | 2011-08-16 | 2013-02-21 | Glaxosmithkline Llc | 5-benzyl-n-phenyethyl-1,3,4-oxadiazole-2-carboxamide derivatives |
EP2871181B1 (en) * | 2013-11-12 | 2016-10-05 | Acousia Therapeutics GmbH | Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues |
CN105769860A (en) * | 2016-04-18 | 2016-07-20 | 乔海灵 | Application of clomethiazole as medicine for preventing and treating liver and esophageal disease |
WO2017222915A1 (en) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Heterocyclic prolinamide derivatives |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
JP2019524807A (en) * | 2016-08-08 | 2019-09-05 | シグナム バイオサイエンシーズ, インコーポレイテッド | Pharmaceutical dosage forms and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2004137480A (en) * | 2002-05-20 | 2005-08-10 | Бристол-Маерс Сквибб Компани (Us) | Hepatitis C Virus Inhibitors |
RU2004133044A (en) * | 2002-04-11 | 2006-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | SERINE PROTEASES INHIBITORS, IN PARTICULAR, NS3-NS4A HCV PROTEASES |
RU2006105002A (en) * | 2003-07-18 | 2006-08-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Inhibitors of serine proteases, in particular, HC-3-HC4A proteases |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (en) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | Chemically modified protein, its production method and intermediate |
US5041426A (en) | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
DE3803225A1 (en) * | 1988-02-04 | 1989-08-17 | Hoechst Ag | AMINO ACID AMIDE WITH PSYCHOTROPIC EFFECT, METHOD FOR THE PRODUCTION THEREOF, AGENTS CONTAINING THE SAME AND THEIR USE |
KR0148748B1 (en) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | A multiphase cyclosporin composition |
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
AU7675491A (en) | 1990-04-04 | 1991-10-30 | Chiron Corporation | Hepatitis c virus protease |
DK0527815T3 (en) | 1990-04-06 | 2000-11-06 | Genelabs Tech Inc | Hepatitis C virus epitope |
SK278808B6 (en) | 1990-11-02 | 1998-03-04 | Novartis Ag | Cyclosporines, their use at the preparation of drug for treating and preventing aids, preparation method thereof and fungal strains useable at this method |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
KR100360964B1 (en) | 1992-12-29 | 2002-11-22 | 아보트 러보러터리즈 | Processes for preparing the intermediates of the retroviral protease inhibiting compounds |
WO1994019012A2 (en) | 1993-02-24 | 1994-09-01 | Wang Jui H | Compositions and methods of application of reactive antiviral polymers |
WO1995003056A1 (en) | 1993-07-19 | 1995-02-02 | Tokyo Tanabe Company Limited | Hepatitis c virus proliferation inhibitor |
PT730470E (en) | 1993-11-10 | 2002-08-30 | Enzon Inc | IMPROVED INTERFERENCE-POLYMER CONJUGATES |
DE4415539C2 (en) | 1994-05-03 | 1996-08-01 | Osama Dr Dr Med Omer | Plants with virustatic and antiviral effects |
DE69524962D1 (en) | 1994-08-22 | 2002-02-14 | Welfide Corp | BENZENE DERIVATIVES AND THEIR MEDICAL USE |
DE4432623A1 (en) | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Process for bleaching aqueous surfactant solutions |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JP3786447B2 (en) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Preventive and therapeutic agent for hepatitis C |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
AU2064297A (en) | 1996-02-29 | 1997-09-16 | Immusol, Inc | Hepatitis c virus ribozymes |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
HUP0004421A3 (en) | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
US5891874A (en) | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
US5837257A (en) | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
JP3927630B2 (en) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Preventive and therapeutic agents for viral infections |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
BR9712544B1 (en) | 1996-10-18 | 2013-10-22 | SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES | |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
IL119833A (en) | 1996-12-15 | 2001-01-11 | Lavie David | Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
EP0966465B1 (en) | 1997-03-14 | 2003-07-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
US6214873B1 (en) | 1997-04-04 | 2001-04-10 | Welfide Corporation | 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
KR100630506B1 (en) | 1997-06-30 | 2006-09-29 | 메르츠 파마 게엠베하 운트 코. 카가아 | 1-amino-alkylcyclohexane compounds as nmda receptor antagonists, pharmaceutical compositions comprising the same and method of treating therewith |
EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
EP1058686B1 (en) | 1998-02-25 | 2006-11-02 | Emory University | 2'-fluoronucleosides |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
WO2000009531A2 (en) | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
EE200100492A (en) | 1999-03-19 | 2002-12-16 | Vertex Pharmaceuticals Incorporated | IMPDH inhibitors |
BR0009564A (en) | 1999-04-07 | 2002-01-08 | Pfizer Prod Inc | Use of cyp2d6 inhibitors in combination therapies |
CN1387606A (en) | 1999-09-06 | 2002-12-25 | 创新内燃机技术股份有限公司 | Internal combustion engine for motor vehicle and method for operating same |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
EA200200778A1 (en) | 2000-02-18 | 2003-06-26 | Шайре Байокем Инк. | METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION |
BR0110023A (en) | 2000-04-13 | 2003-12-30 | Pharmasset Ltd | Substituted 3'-or-2 'nucleoside derivatives for treatment of hepatitis virus infections |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EP1294735A2 (en) | 2000-05-26 | 2003-03-26 | Novirio Pharmaceuticals Limited | Methods and compositions for treating flaviviruses and pestiviruses |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
KR100812578B1 (en) | 2000-07-13 | 2008-03-13 | 상꾜 가부시키가이샤 | Amino alcohol derivatives |
RU2003105221A (en) | 2000-07-21 | 2004-09-20 | Шеринг Корпорейшн (US) | NEW PEPTIDES AS INHIBITORS OF NS3-SERIN PROTEASES OF HEPATITIS C VIRUS |
AU2001276988B2 (en) * | 2000-07-21 | 2007-01-25 | Dendreon Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
EP1301527A2 (en) | 2000-07-21 | 2003-04-16 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
AR029851A1 (en) | 2000-07-21 | 2003-07-16 | Dendreon Corp | NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
AU2001255070A1 (en) | 2000-08-28 | 2002-03-13 | Jin-Sub Kim | Generator of two-wheeled vehicle and lighting system thereby |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
SV2003000617A (en) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
JP2004507552A (en) | 2000-08-31 | 2004-03-11 | メルク エンド カムパニー インコーポレーテッド | Phosphate derivatives as immunomodulators |
KR101201552B1 (en) | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
BR0115447A (en) | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Hepatitis C Tripeptide Inhibitors |
WO2002048172A2 (en) | 2000-12-12 | 2002-06-20 | Schering Corporation | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
US6727366B2 (en) | 2000-12-13 | 2004-04-27 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors |
AU2002232660A1 (en) | 2000-12-15 | 2002-06-24 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
RS50236B (en) | 2001-01-22 | 2009-07-15 | Merck & Co.Inc., | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
DE10102928B4 (en) | 2001-01-23 | 2004-03-04 | Infineon Technologies Ag | Viterbi decoder and method for decoding |
ATE314383T1 (en) | 2001-03-26 | 2006-01-15 | Novartis Pharma Gmbh | 2-AMINO-PROPANOL DERIVATIVES |
JP2002316985A (en) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | Benzothiophene derivative |
DE60235900D1 (en) | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | OSUPPRESSIVUM |
KR100913269B1 (en) | 2001-09-27 | 2009-08-21 | 교린 세이야꾸 가부시키 가이샤 | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
EP1435974A4 (en) * | 2001-09-28 | 2006-09-06 | Idenix Cayman Ltd | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
CN101033242A (en) | 2001-11-27 | 2007-09-12 | 安那迪斯药品股份有限公司 | Antenna system for a level measurement apparatus |
US6973322B2 (en) | 2001-12-22 | 2005-12-06 | International Business Machines Corporation | Personal travel agent using push services |
EP1575964B1 (en) | 2002-01-18 | 2009-11-11 | Merck & Co., Inc. | N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
ATE441654T1 (en) | 2002-01-18 | 2009-09-15 | Merck & Co Inc | EDG RECEPTOR AGONISTS |
MXPA04007163A (en) | 2002-01-23 | 2004-10-29 | Schering Corp | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection. |
KR20050035194A (en) | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
RU2375350C2 (en) | 2003-06-04 | 2009-12-10 | Смитклайн Бичам Корпорейшн | Nitrogen-containing heteroaryl derivatives |
EP1633711B1 (en) | 2003-06-17 | 2010-11-24 | Schering Corporation | Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof |
CN1829709A (en) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | Bicyclic imidazol derivatives against flaviviridae |
JP4527722B2 (en) | 2003-08-26 | 2010-08-18 | シェーリング コーポレイション | Novel peptidomimetic NS3-serine protease inhibitor of hepatitis C virus |
MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
NZ545536A (en) | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
TW200526686A (en) | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
KR20060130027A (en) * | 2003-10-10 | 2006-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
MXPA06004723A (en) * | 2003-10-27 | 2006-07-05 | Vertex Pharma | Combinations for hcv treatment. |
TW200518746A (en) | 2003-12-11 | 2005-06-16 | Schering Corp | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease |
AU2005212257A1 (en) | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
BRPI0507026A (en) | 2004-02-09 | 2007-04-17 | Human Genome Sciences Inc | albumin fusion proteins |
BRPI0508095A (en) | 2004-02-27 | 2007-07-17 | Schering Corp | compounds as inhibitors of hepatitis c virus ns3 serine protease |
US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
KR20060124725A (en) * | 2004-02-27 | 2006-12-05 | 쉐링 코포레이션 | Inhibitors of hepatitis c virus ns3 protease |
WO2005087730A1 (en) | 2004-02-27 | 2005-09-22 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
AU2005219824B2 (en) | 2004-02-27 | 2007-11-29 | Merck Sharp & Dohme Corp. | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
NZ549223A (en) | 2004-02-27 | 2010-10-29 | Schering Corp | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
AR049635A1 (en) | 2004-05-06 | 2006-08-23 | Schering Corp | (1R, 2S, 5S) -N - ((1S) -3-AMINO-1- (CYCLLOBUTILMETIL) -2,3-DIOXOPROPIL) -3 - ((2S) -2 - (((((1,1-DIMETILETIL ) AMINO) CARBONIL) AMINO) -3,3-DIMETIL-1-OXOBUTIL) -6,6-DIMETIL-3-AZABICICLO (3.1.0) HEXAN-2-CARBOXAMIDE AS INHIBITOR OF THE NS3 / NS4A SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
CN1964985A (en) | 2004-06-07 | 2007-05-16 | 阿纳迪斯药物公司 | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof |
US20060089385A1 (en) | 2004-06-08 | 2006-04-27 | Yong Cui | Pharmaceutical compositions |
AU2005271831A1 (en) * | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
WO2006026352A1 (en) | 2004-08-27 | 2006-03-09 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
MX2007003812A (en) | 2004-10-01 | 2007-05-24 | Vertex Pharma | Hcv ns3-ns4a protease inhibition. |
PL1793844T3 (en) | 2004-10-01 | 2011-05-31 | Debiopharm Sa | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection |
KR101309409B1 (en) | 2004-10-01 | 2013-09-23 | 싸이넥시스, 인크. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
MY141025A (en) | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
WO2006076529A1 (en) | 2005-01-14 | 2006-07-20 | Genelabs Technologies, Inc. | Indole derivatives for treating viral infections |
US20070004635A1 (en) | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
WO2006130687A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
WO2006130626A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
NZ565540A (en) | 2005-08-02 | 2011-06-30 | Vertex Pharma | Inhibitors of serine proteases |
AR055395A1 (en) | 2005-08-26 | 2007-08-22 | Vertex Pharma | INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS |
US20070265281A1 (en) | 2006-04-11 | 2007-11-15 | Sylvain Cottens | Organic Compounds and Their Uses |
CA2648298A1 (en) | 2006-04-11 | 2007-10-25 | Novartis Ag | Organic compounds and their uses |
CN101466727B (en) * | 2006-04-11 | 2012-10-17 | 诺瓦提斯公司 | Hcv/hiv inhibitor and their uses |
WO2007120595A2 (en) | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
KR101396696B1 (en) * | 2007-10-10 | 2014-05-16 | 노파르티스 아게 | Spiropyrrolidines and their use against hcv and hiv infection |
US8512690B2 (en) * | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
-
2007
- 2007-04-09 CN CN2007800213542A patent/CN101466727B/en not_active Expired - Fee Related
- 2007-04-09 AU AU2007249668A patent/AU2007249668B2/en not_active Ceased
- 2007-04-09 NZ NZ571826A patent/NZ571826A/en not_active IP Right Cessation
- 2007-04-09 EP EP20070811837 patent/EP2007789B1/en active Active
- 2007-04-09 RU RU2008144299/04A patent/RU2448976C2/en not_active IP Right Cessation
- 2007-04-09 ES ES07811837.9T patent/ES2543840T3/en active Active
- 2007-04-09 JP JP2009505555A patent/JP5167244B2/en not_active Expired - Fee Related
- 2007-04-09 MX MX2008013119A patent/MX2008013119A/en active IP Right Grant
- 2007-04-09 KR KR1020087027485A patent/KR101059593B1/en not_active IP Right Cessation
- 2007-04-09 EP EP12178373A patent/EP2518079A3/en not_active Withdrawn
- 2007-04-09 UA UAA200811685A patent/UA100666C2/en unknown
- 2007-04-09 WO PCT/US2007/066204 patent/WO2007133865A2/en active Application Filing
- 2007-04-09 SG SG2011050440A patent/SG173368A1/en unknown
- 2007-04-09 BR BRPI0710878 patent/BRPI0710878A2/en not_active IP Right Cessation
- 2007-04-09 US US11/697,894 patent/US7825152B2/en not_active Expired - Fee Related
- 2007-04-09 CA CA002643680A patent/CA2643680A1/en not_active Abandoned
- 2007-04-10 PE PE2007000436A patent/PE20080072A1/en not_active Application Discontinuation
- 2007-04-10 CL CL200701005A patent/CL2007001005A1/en unknown
- 2007-04-10 AR ARP070101503A patent/AR060405A1/en unknown
- 2007-04-10 TW TW096112533A patent/TWI341207B/en not_active IP Right Cessation
- 2007-04-10 PE PE2012000534A patent/PE20121157A1/en not_active Application Discontinuation
-
2008
- 2008-09-28 IL IL194434A patent/IL194434A0/en unknown
- 2008-10-01 CR CR10336A patent/CR10336A/en not_active Application Discontinuation
- 2008-10-06 MY MYPI20083963A patent/MY147247A/en unknown
- 2008-10-09 EC EC2008008811A patent/ECSP088811A/en unknown
- 2008-10-10 TN TNP2008000400A patent/TNSN08400A1/en unknown
- 2008-11-03 MA MA31345A patent/MA30392B1/en unknown
- 2008-11-10 NO NO20084749A patent/NO20084749L/en not_active Application Discontinuation
-
2009
- 2009-06-29 HK HK09105830.4A patent/HK1126798A1/en not_active IP Right Cessation
-
2010
- 2010-09-10 US US12/879,644 patent/US8211932B2/en not_active Expired - Fee Related
-
2012
- 2012-05-22 US US13/477,866 patent/US8445527B2/en not_active Expired - Fee Related
-
2013
- 2013-02-11 US US13/764,509 patent/US20130149281A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2004133044A (en) * | 2002-04-11 | 2006-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | SERINE PROTEASES INHIBITORS, IN PARTICULAR, NS3-NS4A HCV PROTEASES |
RU2004137480A (en) * | 2002-05-20 | 2005-08-10 | Бристол-Маерс Сквибб Компани (Us) | Hepatitis C Virus Inhibitors |
RU2006105002A (en) * | 2003-07-18 | 2006-08-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Inhibitors of serine proteases, in particular, HC-3-HC4A proteases |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2448976C2 (en) | Hcv/hiv inhibitors and their application | |
RU2495044C2 (en) | Protein tyrosine kinase activity inhibitors | |
RU2371433C2 (en) | Phenyl substituted pyrrolidones | |
AR047076A1 (en) | PIRROLOTRIAZINE COMPOUNDS AS THYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS | |
EA200970461A1 (en) | SUBSTITUTED DERIVATIVES 3-ISOBUTYL-9,10-DIMETOXI-1,3,4,6,7,11b-HEXAHYDRO-2H-PYRIDO [2,1-a] IZOHINOLIN-2-OLA AND RELATED METHODS | |
AR049646A1 (en) | USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | |
AR057380A1 (en) | CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE AND THERAPEUTIC USE OF THE SAME | |
HK1110868A1 (en) | Heterocyclic compounds as ccr2b antagonists | |
AR045595A1 (en) | USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS | |
AR054482A1 (en) | DERIVATIVES OF AZETIDINONE FOR THE TREATMENT OF HYPERLIPIDEMIAS | |
ECSP066760A (en) | DERIVED FROM 4-OXOPIRIMIDINE CONDENSED RINGS | |
PE20070218A1 (en) | AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE | |
EA200970510A1 (en) | HETEROMONOCYCLIC COMPOUND AND ITS APPLICATION | |
EA200800924A1 (en) | NEW CONNECTIONS OWNED WITH INHIBITING ACTIVITY WITH RESPECT TO SODI-DEPENDENT TRANSPORTER | |
EA200702058A1 (en) | NEW PHARMACEUTICAL COMPOUNDS | |
PE20040937A1 (en) | DERIVATIVES OF PYRIDAZIN-3 (2H) -ONE AS INHIBITORS OF PHOSPHODIESTERASE-4 (PDE 4) | |
AR053120A1 (en) | AMINOPIRIDINS AS INHIBITORS OF BETA SECRETASA | |
EA201000101A1 (en) | DERIVATIVES OF PYRIMIDINE 934 | |
EA200401613A1 (en) | Drug for cancer treatment | |
RU2013119129A (en) | ORGANIC COMPOUNDS | |
BRPI0615248A2 (en) | derivative having ppar agonist activity | |
AR060623A1 (en) | COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD | |
RU2006109004A (en) | 7-AMINOalkylidenylheterocyclic quinolones and naphthyridones | |
AR110443A1 (en) | HISTONE METHYLTRANSPHERASES INHIBITORS | |
CO6230986A2 (en) | COMPOSITE OF 4-PYRIDINONE AND ITS USE FOR CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160410 |